Teligent is a specialty generic pharmaceutical company (NASDAQ: TLGT). Our mission is to be a leading player in the specialty generic prescription drug market.
We have 16 Abbreviated New Drub Applications (ANDAs) on file at the FDA, representing a total addressable market of approximately $1.4 billion (IQVIA, April 2019).
We sell a portfolio of prescription topical medicines and a growing number of hospital-based sterile injectable products, including cephalosporins.
"We are forging the path to profitable growth and will continue to make the tough decisions needed to grow this business responsibly."
Teligent, Inc. Announces Third Quarter 2019 Results
BUENA, N.J. , Nov. 04, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pha...Learn More
Teligent, Inc. to Hold Conference Call for Third Quarter 2019 Results on Monday November 4th, 2019
BUENA, N.J. , Oct. 31, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pha...Learn More
Teligent Announces the Pricing of $34.4 Million of Series B Senior Convertible Notes
BUENA, N.J. , Oct. 28, 2019 (GLOBE NEWSWIRE) -- Teligent , Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jers...Learn More